Autonomix Medical, Inc. (AMIX) company profile
Close on Nov 17, 2026Market cap $1.05MP/E –Yield –
About Autonomix Medical
Surgical & Medical Instruments & Apparatus, SIC 3841
Autonomix Medical is a development-stage medical device enterprise focused on advancing diagnostic and therapeutic technologies for nervous system disorders. The company develops a catheter-based platform that combines high-sensitivity neural signal detection with targeted radiofrequency ablation, utilizing a "sense, treat, verify" approach to improve procedural precision. Its primary offerings comprise a proprietary microchip-enabled sensing catheter, an RF ablation catheter, a dedicated RF generator, and visualization software. Designed to navigate transvascular pathways, these systems target peripheral nerve fibers initially to manage pain associated with pancreatic cancer. The technology is tailored for interventional radiologists and cardiologists operating in hospital catheter laboratories, with potential future applications covering additional visceral pain conditions, hypertension, and other nerve-related disorders.
The company operates without commercial facilities or retail locations, functioning through prototype development, third-party manufacturing partnerships, and clinical trial sites. It maintains an international intellectual property portfolio covering technologies across the United States, Europe, Canada, Australia, China, India, Japan, Mexico, and Singapore. The provided report does not state the specific location of its corporate headquarters.
Summary of the business section of Autonomix Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Autonomix Medical, Inc.
- Headquarters
- The Woodlands, TX
- Address
- 21 Waterway Avenue, Suite 300 77380
- Phone
- (832) 277-7816
- Website
- autonomix.com
- Employees
- 11, Mar 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- March 31
- Auditor
- ForvisMazars,LLP, Atlanta, Georgia
Stock & identifiers
- Ticker
- AMIX
- Exchange
- Nasdaq
- IPO date
- Jan 29, 2024
- Shares outstanding
- 1M, Aug 6, 2026
- Public float
- $6.31M, Sep 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-21 reverse, Jun 24, 2026; 1-for-13.5 reverse, Nov 8, 2024; 1-for-20 reverse, Oct 25, 2024
- SEC CIK
- 1617867
- CUSIP
- 05330T304
- ISIN
- US05330T3041
- FIGI
- BBG00R28GXW5
- Share class FIGI
- BBG00R28GXX4
- EIN
- 47-1607810
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Trent N. Smith | CFO | 15,119 |
| Bradley Hauser | CEO and President | 27,000 |
| Sandra C. Kalter | Director | – |
| Lori Bisson | Director | 13,119 |
| Walter V. Klemp | Director | 20,118 |
| Christopher Capelli | Director | – |
Executive compensation, fiscal 2026
Summary compensation table from the latest proxy statement
| Executive | Salary | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|
| Brad Hauser Chief Executive Officer and President | $468.00K | $202.18K | $670.18K | -60% |
| Lori Bisson Executive Vice Chairman | $150.00K | $54.00K | $204.00K | -69% |
| Trent Smith Chief Financial Officer | $296.40K | $85.36K | $381.76K | -38% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 25, 2024
- Offer price
- $6.54
- Securities offered
- 458,691
- Gross proceeds
- $3.00M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- May 24, 2025
“Per Common Stock Unit Per PFW Unit Total Public offering price $ 6.5400 $ 6.53900 $ 8,999,999.38 Underwriting discounts and commissions (1) $ 0.5232 $ 0.52312 $ 719,999.95 Proceeds, before expenses, to us (2) $ 6.0168 $ 6.01588 $ 8,279,999.43 (1) Represents underwriting discounts equal to 8% per Common Stock Unit or PFW Unit, as applicable”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 31, 2025, we have 11 employees providing services to the Company, eight on a full-time basis and three on a part-time basis.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 16, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 20, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 26, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?